COMPLETED

THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to pilot and refine an online behavioral intervention based on Positive Affect Training (PAT) that aims to increase positive emotional attitudes and decrease negative emotional attitudes toward endocrine therapy (ET, i.e., anti-hormonal medication) and to increase positive affect and decrease negative affect more generally, among post-treatment breast cancer survivors who are prescribed ET to prevent recurrence of breast cancer.

Official Title

Pilot Study of Positive Affect Training for Endocrine Therapy Medication Adherence

Quick Facts

Study Start:2024-03-12
Study Completion:2025-04-18
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06388304

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * hormone receptor-positive breast cancer stages 0-3
  2. * have finished primary treatment (chemotherapy/radiation/surgery)
  3. * are prescribed endocrine therapy (ET) currently or within the last two years
  4. * score above specified cut off (range, 0-10) on any of three questions:
  5. 1. How upset are you by having to take anti-hormonal therapy
  6. 2. How bothered are you by the side effects?
  7. 3. How difficult is it for you to take your anti-hormonal medication every day?
  8. * have internet access to complete online assessments and intervention components or agree to use and return a study wifi-activated iPad.
  1. * metastatic disease
  2. * Individuals who are unable to interact with the intervention as needed. This includes those who are extremely visually impaired to the degree that they cannot see the screen and interact as required and individuals who cannot read and/or write in English. This is due to the nature of the intervention itself. If a participant is unable to interact with THRIVE as required, they are unlikely to benefit from the intervention or offer insightful feedback that can be used in refining the program.

Contacts and Locations

Principal Investigator

Joanna Arch, PhD
PRINCIPAL_INVESTIGATOR
University of Colorado, Boulder

Study Locations (Sites)

University of Colorado Boulder
Boulder, Colorado, 80309
United States

Collaborators and Investigators

Sponsor: Joanna Arch

  • Joanna Arch, PhD, PRINCIPAL_INVESTIGATOR, University of Colorado, Boulder

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-12
Study Completion Date2025-04-18

Study Record Updates

Study Start Date2024-03-12
Study Completion Date2025-04-18

Terms related to this study

Additional Relevant MeSH Terms

  • Breast Cancer
  • DCIS